Hoth Therapeutics (HOTH) to Release Earnings on Friday

Hoth Therapeutics (NASDAQ:HOTH) is expected to issue its results before the market opens on Friday, March 27th. Analysts expect the company to announce earnings of ($0.1031) per share for the quarter.

Hoth Therapeutics Stock Down 6.7%

HOTH opened at $0.92 on Friday. The stock has a market cap of $14.32 million, a PE ratio of -0.87 and a beta of 0.50. Hoth Therapeutics has a twelve month low of $0.66 and a twelve month high of $2.12. The company has a fifty day moving average of $1.00 and a 200-day moving average of $1.22.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. D. Boral Capital restated a “buy” rating and set a $5.00 price target on shares of Hoth Therapeutics in a report on Wednesday, March 4th. Wall Street Zen upgraded shares of Hoth Therapeutics to a “sell” rating in a research note on Saturday, March 7th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Hoth Therapeutics in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Hoth Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $5.00.

Institutional Trading of Hoth Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its holdings in shares of Hoth Therapeutics by 8.0% in the 2nd quarter. Geode Capital Management LLC now owns 122,575 shares of the company’s stock worth $143,000 after acquiring an additional 9,071 shares during the last quarter. Virtu Financial LLC bought a new stake in Hoth Therapeutics during the 3rd quarter worth approximately $184,000. Citadel Advisors LLC bought a new stake in Hoth Therapeutics during the 3rd quarter worth approximately $232,000. Lido Advisors LLC purchased a new stake in shares of Hoth Therapeutics in the third quarter worth approximately $32,000. Finally, Kestra Private Wealth Services LLC purchased a new stake in shares of Hoth Therapeutics in the third quarter worth approximately $51,000. Institutional investors own 7.08% of the company’s stock.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.